IGFBP-3 Antibody [Biotin]

• Reactivity: Hu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

IGFBP-3 Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IGFBP‑3 (R&D Systems, Catalog # 675-B3)
  Gly28-Lys291
  Accession # CAA46087
• Specificity: Detects human IGFBP-3 in ELISAs and Western blots. In sandwich immunoassays, less than 0.3% cross-reactivity with recombinant human (rh) IGFBP‑1, rhIGFBP-2, rhIGFBP-4, rhIGFBP-5 and rhIGFBP-6 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IGFBP3
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Human IGFBP-3 Antibody (Catalog # MAB305)
  ELISA Detection: Human IGFBP-3 Biotinylated Antibody (Catalog # BAF675)
  Standard: Recombinant Human IGFBP-3 (Catalog # 675-B3)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-3 Antibody [Biotin]

• acid stable subunit of the 140 K IGF complex
• binding protein 29
• binding protein 53
• growth hormone-dependent binding protein
• IBP-3
• IBP3BP-53
• IGF-binding protein 3
• IGFBP3
• IGFBP-3
• insulin-like growth factor binding protein 3
• insulin-like growth factor-binding protein 3

Background

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-3 cDNA encodes a 291 amino acid (aa) residue precursor protein with a putative 27 aa residue signal peptide that is processed to generate the 264 aa residue mature protein with three potential N-linked and two potential O-linked glycosylation sites. Human IGFBP-3 is expressed in multiple tissues. The highest expression level is found in the non-paranchymal cells of the liver. Expression levels are also higher during extrauterine life and peak during puberty. Human IGFBP-3 is the major IGF binding protein in plasma where it exists in a ternary complex with IGF-I or IGF-II and the acid-labile subunit (ALS).

1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
3. Spagnoli, A. and R.G. Rosenfeld (1997) Curr. Op. Endocrinology and Diabetes 4:1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGFBP-3 Antibody (BAF675)(5)

Publications using BAF675

• Jacob Thomsen, Rikke Hjortebjerg, Ulrick Espelund, Gitte Ørtoft, Poul Vestergaard, Nils E. Magnusson et al. PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma Oncotarget 8/24/2015 [PMID: 26336825]
• Jacob Thomsen, Rikke Hjortebjerg, Ulrick Espelund, Gitte Ørtoft, Poul Vestergaard, Nils E. Magnusson et al. PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma Oncotarget 2015-08-24 [PMID: 26336825] (Western Blot, Human)
• Musil , J, Kutinova , L, Zurkova , K, Hainz , P, Babiarova , K, Krystofova , J, Nemeckova , S Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3. Cancer Gene Ther, 2014-02-21;21(3):115-25. 2014-02-21 [PMID: 24556712] (Western Blot, Virus)
• Victoria A. Brown, Ketan R. Patel, Maria Viskaduraki, James A. Crowell, Marjorie Perloff, Tristan D. Booth et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis Cancer Research 11/15/2010 [PMID: 20935227]
• Kirman I, Poltoratskaia N, Sylla P, Whelan RL Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery, 2004-08-01;136(2):205-9. 2004-08-01 [PMID: 15300181] (Western Blot, Mouse)

Bioinformatics

• Gene Symbol: IGFBP3
• Uniprot:
  • CAA46087()